{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:54:08Z","timestamp":1792518848668,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but with relapses with treatment, refractory disease is the most common outcome, especially in CLL with the deletion of chromosome 11q or 17p. In addressing the need of treatments for relapsed disease, we report the identification of an existing U.S. Food and Drug Administration-approved small-molecule drug to repurpose for CLL treatment. Auranofin (Ridaura) is approved for use in treating rheumatoid arthritis, but it exhibited preclinical efficacy in CLL cells. By inhibiting thioredoxin reductase activity and increasing intracellular reactive oxygen species levels, auranofin induced a lethal endoplasmic reticulum stress response in cultured and primary CLL cells. In addition, auranofin displayed synergistic lethality with heme oxygenase-1 and glutamate-cysteine ligase inhibitors against CLL cells. Auranofin overcame apoptosis resistance mediated by protective stromal cells, and it also killed primary CLL cells with deletion of chromosome 11q or 17p. In TCL-1 transgenic mice, an in vivo model of CLL, auranofin treatment markedly reduced tumor cell burden and improved mouse survival. Our results provide a rationale to reposition the approved drug auranofin for clinical evaluation in the therapy of CLL. Cancer Res; 74(9); 2520\u201332. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-2033","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T23:17:00Z","timestamp":1394061420000},"page":"2520-2532","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":239,"title":["Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia"],"prefix":"10.1158","volume":"74","author":[{"given":"Warren","family":"Fiskus","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle","family":"Saba","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondana","family":"Ghias","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyasri Das","family":"Gupta","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lata","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Rao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Gunewardena","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schorno","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Austin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Byrd","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Melnick","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Houston Methodist Research Institute; 2The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3Hematology Branch, National Heart Lung and Blood Institute (NHLBI); 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; 5The University of Kansas Medical Center; 6Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; 7Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and 8Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"key":"2022061704564282400_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022061704564282400_bib2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061704564282400_bib3","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","article-title":"Risk categories and refractory CLL in the era of chemoimmunotherapy","volume":"119","author":"Zenz","year":"2012","journal-title":"Blood"},{"key":"2022061704564282400_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/0008-5472.CAN-11-3439","article-title":"Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership","volume":"72","author":"Weir","year":"2012","journal-title":"Cancer Res"},{"key":"2022061704564282400_bib5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-11-2113","article-title":"ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K\/AKT inhibition and induction of oxidative stress","volume":"18","author":"Chapman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061704564282400_bib6","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood-2008-04-149815","article-title":"Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism","volume":"112","author":"Trachootham","year":"2008","journal-title":"Blood"},{"key":"2022061704564282400_bib7","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","article-title":"Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents","volume":"101","author":"Zhou","year":"2003","journal-title":"Blood"},{"key":"2022061704564282400_bib8","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1089\/ars.2008.2063","article-title":"Thiol chemistry in peroxidase catalysis and redox signaling","volume":"10","author":"Bindoli","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"2022061704564282400_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2022061704564282400_bib10","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1093\/nar\/gkq212","article-title":"Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis","volume":"38","author":"Malhotra","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2022061704564282400_bib11","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1073\/pnas.1002890107","article-title":"Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704564282400_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/BJ20101695","article-title":"Molecular targets of oxidative stress","volume":"434","author":"Avery","year":"2011","journal-title":"Biochem J"},{"key":"2022061704564282400_bib13","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Genes Dev"},{"key":"2022061704564282400_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4161\/cc.7.1.5186","article-title":"HDAC6 a new cellular stress surveillance factor","volume":"7","author":"Matthias","year":"2008","journal-title":"Cell Cycle"},{"key":"2022061704564282400_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"2022061704564282400_bib16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-09-0988","article-title":"Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells","volume":"9","author":"Rao","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022061704564282400_bib17","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1158\/0008-5472.CAN-08-0644","article-title":"Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion","volume":"68","author":"Yang","year":"2008","journal-title":"Cancer Res"},{"key":"2022061704564282400_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022061704564282400_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2022061704564282400_bib20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","article-title":"HDAC6 inhibition enhances 17-AAG-mediated abrogation of HSP90 Chaperone function in human leukemia cells","volume":"112","author":"Rao","year":"2008","journal-title":"Blood"},{"key":"2022061704564282400_bib21","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1182\/blood-2005-03-1099","article-title":"ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia","volume":"106","author":"Castro","year":"2005","journal-title":"Blood"},{"key":"2022061704564282400_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ncb0311-184","article-title":"Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress","volume":"13","author":"Tabas","year":"2011","journal-title":"Nat Cell Biol"},{"key":"2022061704564282400_bib23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"2022061704564282400_bib24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1146361","article-title":"IRE1 signaling affects cell fate during the unfolded protein response","volume":"318","author":"Lin","year":"2007","journal-title":"Science"},{"key":"2022061704564282400_bib25","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-10-0529","article-title":"Role of CAAT\/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells","volume":"16","author":"Rao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061704564282400_bib26","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"116","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"2022061704564282400_bib27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"key":"2022061704564282400_bib28","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"2022061704564282400_bib29","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia","volume":"120","author":"Davids","year":"2012","journal-title":"Blood"},{"key":"2022061704564282400_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ncb2432","article-title":"Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia","volume":"14","author":"Zhang","year":"2012","journal-title":"Nat Cell Biol"},{"key":"2022061704564282400_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2009.07.023","article-title":"Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase","volume":"79","author":"Gandin","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"2022061704564282400_bib32","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.4049\/jimmunol.153.7.2951","article-title":"Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes","volume":"153","author":"Kim","year":"1994","journal-title":"J Immunol"},{"key":"2022061704564282400_bib33","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"2022061704564282400_bib34","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704564282400_bib35","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"key":"2022061704564282400_bib36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/leu.2012.63","article-title":"Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia","volume":"26","author":"Sivina","year":"2012","journal-title":"Leukemia"},{"key":"2022061704564282400_bib37","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0090-9556(24)15048-9","article-title":"Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations","volume":"27","author":"Appleton","year":"1999","journal-title":"Drug Metabol Disposit"},{"key":"2022061704564282400_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Reg"},{"key":"2022061704564282400_bib39","doi-asserted-by":"crossref","first-page":"16116","DOI":"10.1074\/jbc.M110.116210","article-title":"Rapid activation of glutamate cysteine ligase following oxidative stress","volume":"285","author":"Krejsa","year":"2010","journal-title":"J Biol Chem"},{"key":"2022061704564282400_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.freeradbiomed.2011.10.493","article-title":"Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress","volume":"52","author":"Scarbrough","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"2022061704564282400_bib41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrm2938","article-title":"Heat shock factors: integrators of cell stress, development and lifespan","volume":"11","author":"Akerfelt","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061704564282400_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat Med"},{"key":"2022061704564282400_bib43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.leukres.2010.01.020","article-title":"Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro","volume":"34","author":"Biswas","year":"2010","journal-title":"Leuk Res"},{"key":"2022061704564282400_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"2022061704564282400_bib45","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2007-07-104042","article-title":"HO-1 underlies resistance of AML cells to TNF-induced apoptosis","volume":"111","author":"Rushworth","year":"2008","journal-title":"Blood"},{"key":"2022061704564282400_bib46","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1158\/0008-5472.CAN-10-1509","article-title":"Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation","volume":"70","author":"Mandal","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704564282400_bib47","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-11-0736","article-title":"Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism","volume":"17","author":"Fath","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061704564282400_bib48","doi-asserted-by":"crossref","first-page":"e48175","DOI":"10.1371\/journal.pone.0048175","article-title":"Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism","volume":"7","author":"Sobhakumari","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/9\/2520\/2717412\/2520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/9\/2520\/2717412\/2520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T20:18:26Z","timestamp":1746130706000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/74\/9\/2520\/599672\/Auranofin-Induces-Lethal-Oxidative-and-Endoplasmic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,4,30]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-2033","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22400703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22400709.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22400706.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22400703.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22400706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22400709","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6505647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6505647.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}